These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 20964458)

  • 1. Clinical pharmacology of direct and indirect factor Xa inhibitors.
    Rupprecht HJ; Blank R
    Drugs; 2010 Nov; 70(16):2153-70. PubMed ID: 20964458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developments in factor Xa inhibitors for the treatment of thromboembolic disorders.
    Lee YK; Player MR
    Med Res Rev; 2011 Mar; 31(2):202-83. PubMed ID: 19967784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism.
    Yong CM; Boyle AJ
    Curr Vasc Pharmacol; 2010 Jan; 8(1):5-11. PubMed ID: 19485937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor Xa inhibitors: new anti-thrombotic agents and their characteristics.
    Ieko M; Tarumi T; Nakabayashi T; Yoshida M; Naito S; Koike T
    Front Biosci; 2006 Jan; 11():232-48. PubMed ID: 16146728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel antithrombotic agents: indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors. Evidences from clinical studies.
    Leone G; Rossi E; Leone AM; De Stefano V
    Curr Med Chem Cardiovasc Hematol Agents; 2004 Oct; 2(4):311-26. PubMed ID: 15320782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
    Eriksson BI; Quinlan DJ; Eikelboom JW
    Annu Rev Med; 2011; 62():41-57. PubMed ID: 21226611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short- and long-acting synthetic pentasaccharides.
    Koopman MM; Büller HR
    J Intern Med; 2003 Oct; 254(4):335-42. PubMed ID: 12974872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
    Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J
    Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
    Graff J; Picard-Willems B; Harder S
    Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
    Gerotziafas GT; Depasse F; Chakroun T; Van Dreden P; Samama MM; Elalamy I
    Blood Coagul Fibrinolysis; 2004 Mar; 15(2):149-56. PubMed ID: 15091002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemistry and clinical pharmacology of new anticoagulant agents.
    Samama MM; Gerotziafas GT; Elalamy I; Horellou MH; Conard J
    Pathophysiol Haemost Thromb; 2002; 32(5-6):218-24. PubMed ID: 13679646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.
    Kubitza D; Haas S
    Expert Opin Investig Drugs; 2006 Aug; 15(8):843-55. PubMed ID: 16859389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct Factor Xa and direct thrombin inhibitors: a clinical trial update.
    Turpie AG
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):497-508. PubMed ID: 19562646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of synthetic factor Xa inhibitors.
    Gerotziafas GT; Samama MM
    Curr Pharm Des; 2005; 11(30):3855-76. PubMed ID: 16305517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants?
    Cohen H; Machin SJ
    Lupus; 2010 Apr; 19(4):486-91. PubMed ID: 20353992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa.
    Petitou M; Duchaussoy P; Herbert JM; Duc G; El Hajji M; Branellec JF; Donat F; Necciari J; Cariou R; Bouthier J; Garrigou E
    Semin Thromb Hemost; 2002 Aug; 28(4):393-402. PubMed ID: 12244487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological strategies for inhibition of thrombin activity.
    Alban S
    Curr Pharm Des; 2008; 14(12):1152-75. PubMed ID: 18473863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.
    Ganetsky VS; Hadley DE; Thomas TF
    Pharmacotherapy; 2014 Jun; 34(6):590-604. PubMed ID: 24338703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban, an oral direct factor Xa inhibitor.
    Piccini JP; Patel MR; Mahaffey KW; Fox KA; Califf RM
    Expert Opin Investig Drugs; 2008 Jun; 17(6):925-37. PubMed ID: 18491993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants?
    Papadaki S; Tselepis AD
    Angiology; 2019 Nov; 70(10):896-907. PubMed ID: 31010298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.